Overview

A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma

Status:
Completed
Trial end date:
2018-07-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate potential biomarkers and method of action, efficacy and safety of olaratumab in participants with soft tissue sarcoma (STS).
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Doxorubicin
Liposomal doxorubicin
Olaratumab